Skip to main content
Clinical Trials/ACTRN12615000957594
ACTRN12615000957594
Completed
未知

A multicentre, randomised, single-blinded clinical trial comparing the effect of conservative oxygen therapy with standard care on ventilator-free days in mechanically ventilated adults in the intensive care unit.

Medical Research Institute of New Zealand0 sites1,000 target enrollmentSeptember 11, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
Critical illness
Sponsor
Medical Research Institute of New Zealand
Enrollment
1000
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 11, 2015
End Date
November 26, 2018
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients at least 18 years of age who require invasive mechanical ventilation in the ICU and are expected to be receiving mechanical ventilation beyond the next calendar day.

Exclusion Criteria

  • After enrollment of 100 participants, in response to feedback from site investigators and research coordinators, the exclusion criteria were amended to read as follows:
  • 1\. Greater than two hours of invasive mechanical ventilation and/ or non\-invasive ventilation in an ICU during this hospital admission (includes time ventilated in another hospital’s ICU)
  • 2\. In the view of the treating clinician, hyperoxia is clinically indicated for reasons including (but not limited to) carbon monoxide poisoning or a requirement for hyperbaric oxygen therapy
  • 3\. In the view of the treating clinician, avoidance of hyperoxia is clinically indicated for reasons including (but not limited to) chronic obstructive airways disease (COPD), paraquat poisoning, previous exposure to bleomycin, or chronic hypercapnic respiratory failure
  • 4\. Pregnancy
  • 5\. Death is deemed to be inevitable as a result of the current acute illness and either the treating clinician, the patient, or the substitute decision maker are not committed to full active treatment
  • 6\. Patients with a life expectancy of less than 90 days due to a chronic or underlying medical condition
  • 7\. Admitted following a drug overdose (including alcohol intoxication)
  • 8\. Long\-term dependence on invasive ventilation prior to this acute illness
  • 9\. Confirmed or suspected diagnosis of any of the following: Guillain\-Barré syndrome, cervical cord injury above C5, muscular dystrophy, or motor neurone disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 4
A Randomized, Single-blind, Multi-center Clinical Study for Artemisinin-Piperazine and Artemether-Benzolol in the Treatment of Uncomplicated Falciparum MalariaMalaria
ITMCTR1900002588Guangzhou University of Chinese Medicine
Active, not recruiting
Phase 1
A clinical trial to evaluate efficacy, safety and cost-efficacy of gene analysis strategy in a population at risk of cardiovascular disease susceptible of receiving high or moderate-intensity doses of statinsPatients at risk of cardiovascular disease susceptible of receiving high or moderate-intensity doses of statins.Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
CTIS2023-509418-12-00Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz216
Not yet recruiting
Phase 3
Effect of Rotataory handle, straight handle and flexible handle toothbrushes in removing Plaque
CTRI/2023/02/049838Dr.Gowri Pendyala
Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency
EUCTR2007-003723-21-DEovartis Pharma Services AG525
Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiency - ND
EUCTR2007-003723-21-ITOVARTIS FARMA300